Physician profile
Ateeq Haseeb
NPI 1194923060
$9,119.12
in general payments reported to CMS, 2019-2025
27 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $350 · 2021: $3,658 · 2022: $930 · 2023: $966 · 2024: $370 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $828 · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $828.00 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $6,948.56 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Supernus Pharmaceuticals, INC. | $337.50 | 2019-2025 | Qelbree |
| Neurelis, INC. | $282.60 | 2023-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $213.27 | 2019-2025 | |
| Ucb, INC. | $186.21 | 2020-2025 | Fintepla, Briviact |
| Acadia Pharmaceuticals INC | $120.02 | 2024-2025 | Daybue |
| Sk Life Science, INC. | $116.63 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $110.74 | 2021 | |
| Eisai INC. | $105.09 | 2019 | |
| Otter Pharmaceuticals, LLC | $96.71 | 2025 | Sympazan |
| Catalyst Pharmaceuticals, INC. | $94.01 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $86.66 | 2021 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $58.45 | 2019 | |
| Biocodex, INC. | $57.65 | 2024 | |
| Greenwich Biosciences, INC. | $40.16 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39.59 | 2021 | |
| Aquestive Therapeutics, INC. | $39.17 | 2020-2025 | |
| Upsher-Smith Laboratories LLC | $26.66 | 2025 | |
| Corium, LLC | $25.79 | 2025 | Azstarys |
| Tris Pharma INC | $21.55 | 2025 | Dyanavel Xr |
| Biomarin Pharmaceutical INC. | $18.62 | 2023 | Brineura |
| Ipsen Biopharmaceuticals, INC | $18.51 | 2019 | |
| Biogen, INC. | $17.63 | 2024 | Spinraza |
| Aucta Pharmaceuticals, INC. | $16.84 | 2025 | Motpoly Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.35 | 2020 | |
| Merz North America, INC. | $13.55 | 2019 | |
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ateeq Haseeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.